| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 09/02/2004 | WO2003099786A3 Aromatic sulfones and their medical use |
| 09/02/2004 | WO2003084344A3 Method of improving absorption of vitamin e by a pet animal |
| 09/02/2004 | US20040171848 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 09/02/2004 | US20040171830 Carboline derivatives as pdev inhibitors |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171689 Screening method using solid supports modified with self-assembled monolayers |
| 09/02/2004 | US20040171686 Agent for prophylaxis or treatment of inflammatory bowel diseases |
| 09/02/2004 | US20040171676 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 09/02/2004 | US20040171647 Reducing adverse side effects using optically pure S form |
| 09/02/2004 | US20040171646 Novel substituted benzimidazole dosage forms and method of using same |
| 09/02/2004 | US20040171639 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 09/02/2004 | US20040171618 Compounds as PDE IV and TNF-inhibitors |
| 09/02/2004 | US20040171617 treatment for disorders and diseases, such as chronic inflammation, tissue breakdown and cancer |
| 09/02/2004 | US20040171607 Chemical compounds |
| 09/02/2004 | US20040171597 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 09/02/2004 | US20040171592 reduced gastric effects; salicylic acid derivatives |
| 09/02/2004 | US20040171582 comprises a lysophosphatidic acid (LPA) receptor modulator; EDG-2 agonist or antagonist |
| 09/02/2004 | US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells |
| 09/02/2004 | US20040171530 Polypeptides containing cysteine and tryptophan |
| 09/02/2004 | US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/02/2004 | US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171123 fusion protein of an antibody that binds to human epidermal growth factor receptor-2 (HER2) and albumin with long shelf-life; stabilizing therapeutic proteins such as antibodies by conjugating them to albumin |
| 09/02/2004 | US20040171117 Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders |
| 09/02/2004 | US20040171018 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170997 used in drug screening for preventing or treating diseases associated with abnormalities in intracellular signal transduction; genetic engineering |
| 09/02/2004 | US20040170995 for drug screening in vitro for mitogen-activated protein kinase-activated protein kinase-2 modulators using expression libraries; genetic engineering; kits |
| 09/02/2004 | US20040170713 To promote good health and as a dietary additive |
| 09/02/2004 | US20040170712 Applying a Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170711 Medical effect of Jojoba oil in the treatment of anal diseases |
| 09/02/2004 | US20040170710 Treating vaginal diseases by applying Jojoba oil extruded from Jojoba seeds |
| 09/02/2004 | US20040170649 uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact; autologous vaccines |
| 09/02/2004 | US20040170648 first valence adjuvanted with an aluminum hydroxide (especially Hepatite A); second valence contains a bacterial capsule polysaccharide with O-acetyl groups (especially typhoid fever valence formed by the polysaccharide Vi of the Salmonella typhi capsule); and phosphate, citrate or carbonate ions. |
| 09/02/2004 | US20040170640 Methods for preparing and delivering adjuvant compositions |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170599 Gastrointestinal disorders; anticancer agents; sustained release |
| 09/02/2004 | US20040170578 Mixture of fluorine compound and photocatalyst; applying to teeth |
| 09/02/2004 | US20040170576 Preparation for saliva flow |
| 09/02/2004 | CA2518313A1 Medicament comprising noble metal fineparticles |
| 09/02/2004 | CA2516021A1 6-substituted imidazopyrazines |
| 09/02/2004 | CA2512928A1 The enantiomer of tenatoprazole and the use thereof in therapy |
| 09/01/2004 | EP1452587A1 Stem cells originating in salivary duet epithelial cells and use thereof |
| 09/01/2004 | EP1452533A1 Crystalline form Z of rabeprazole sodium and process for preparation thereof |
| 09/01/2004 | EP1452527A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| 09/01/2004 | EP1452521A1 Cyclic compound and ppar agonist |
| 09/01/2004 | EP1452181A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/01/2004 | EP1452178A1 Persistent filmy preparation for topical administration containing prostaglandin derivative |
| 09/01/2004 | EP1452172A2 Multiple unit pharmaceutical preparation |
| 09/01/2004 | EP1451578A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451210A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451209A2 Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451202A1 Aryl fused azapolycyclic compounds |
| 09/01/2004 | EP1451196A1 The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| 09/01/2004 | EP1451192A1 Novel crystalline compound |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451190A1 Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451174A2 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers |
| 09/01/2004 | EP1451172A1 Therapeutic isoquinoline compounds |
| 09/01/2004 | EP1451167A1 Phenylalkynes |
| 09/01/2004 | EP1451166A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof |
| 09/01/2004 | EP1451165A1 Substituted benzoxazoles and analogues as estrogenic agents |
| 09/01/2004 | EP1451158A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451157A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 09/01/2004 | EP1451156A1 4-aminoquinoline compounds |
| 09/01/2004 | EP1451153A1 Nk1 antagonists |
| 09/01/2004 | EP1450848A2 Methods of treating liver fibrosis and hepatitis c virus infection |
| 09/01/2004 | EP1450842A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 09/01/2004 | EP1450837A2 Interleukin-1 receptors in the treatment of diseases |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450825A1 Use of selenite-containing compounds to be topically or buccally administered |
| 09/01/2004 | EP1450824A1 Pharmaceutical composition |
| 09/01/2004 | EP1450820A2 Method for treating or preventing inflammatory diseases |
| 09/01/2004 | EP1450819A1 Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
| 09/01/2004 | EP1450818A2 A method for treating inflammatory bowel disease |
| 09/01/2004 | EP1450801A2 2-aminoquinoline compounds |
| 09/01/2004 | EP1450792A1 Benzazole derivatives for the treatment of scleroderma |
| 09/01/2004 | EP1450779A1 Method for treating autoimmune diseases |
| 09/01/2004 | EP1450777A1 Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity |
| 09/01/2004 | EP1450769A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 09/01/2004 | EP1450762A1 Novel formulation |
| 09/01/2004 | EP1450750A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 09/01/2004 | EP1450626A1 A novel non-antibiotic strategy against ogip infections based on an activated cereal product or ferric quinate |
| 09/01/2004 | EP1450610A2 Probiotic compositions |
| 09/01/2004 | EP1261349A4 Compounds with chelation affinity and selectivity for first transition series elements and their use |
| 09/01/2004 | EP1242410B1 Novel compounds |
| 09/01/2004 | EP1221443B1 Substituted imidazolidinone derivatives |
| 09/01/2004 | EP1165528B1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 09/01/2004 | EP1127058B1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 09/01/2004 | EP1121064B1 Method and device for preparing a dental implant by immersion in a mesenchymal cell culture |
| 09/01/2004 | EP1047769B1 Novel therapeutic uses of heterologous superoxide dismutase (hsd), and method for selecting said hsd |
| 09/01/2004 | EP0984955B1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing tnf alpha levels |
| 09/01/2004 | EP0944621B1 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
| 09/01/2004 | EP0923530B1 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| 09/01/2004 | CN1525978A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |